LncRNA MALAT1 Regulating Lung Carcinoma Progression via the miR-491-5p/UBE2C Axis. 2021

Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
Cancer Research Institute, Binzhou Medical University Hospital, Binzhou, China.

Long noncoding RNAs (lncRNAs) play a critical role in the development of lung carcinoma. The mechanism of MALAT1 in lung carcinoma development is not understood very well. This study aimed to investigate the role of MALAT1 in lung carcinoma progression and the mechanism underlying the role of miR-491-5p in the MALAT1 mediated regulation of UBE2C expression. The results indicated that the expression of MALAT1 was often augmented in lung carcinoma cells. Suppression of MALAT1 blocked the proliferation, invasion and migration ability of cancer cells and inhibited the expression of UBE2C. UBE2C restoration attenuated the MALAT1 knockdown-induced anti-cancer effects. Moreover, UBE2C and MALAT1 were indicated as targets of miR-491-5p and inhibition of miR-491-5p restored the MALAT1 knockdown-induced inhibition of the progression of lung carcinoma. Furthermore, MALAT1 sponged miR-491-5p to upregulate UBE2C expression, causing it to act as a competing endogenous RNA. Collectively, MALAT1 downregulation suppressed lung carcinoma progression by regulating the miR-491-5p/UBE2C axis. These results indicate that MALAT1 could be a molecular target for lung carcinoma treatment and prognosis.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D044763 Ubiquitin-Conjugating Enzymes A class of enzymes that form a thioester bond to UBIQUITIN with the assistance of UBIQUITIN-ACTIVATING ENZYMES. They transfer ubiquitin to the LYSINE of a substrate protein with the assistance of UBIQUITIN-PROTEIN LIGASES. Ubiquitin-Conjugating Enzyme,HHR6 Protein,Ubiquitin-Conjugating Enzyme E2,E2, Ubiquitin-Conjugating Enzyme,Enzyme E2, Ubiquitin-Conjugating,Enzyme, Ubiquitin-Conjugating,Enzymes, Ubiquitin-Conjugating,Ubiquitin Conjugating Enzyme,Ubiquitin Conjugating Enzyme E2,Ubiquitin Conjugating Enzymes
D062085 RNA, Long Noncoding A class of untranslated RNA molecules that are typically greater than 200 nucleotides in length and do not code for proteins. Members of this class have been found to play roles in transcriptional regulation, post-transcriptional processing, CHROMATIN REMODELING, and in the epigenetic control of chromatin. LincRNA,RNA, Long Untranslated,LINC RNA,LincRNAs,Long Intergenic Non-Protein Coding RNA,Long Non-Coding RNA,Long Non-Protein-Coding RNA,Long Noncoding RNA,Long ncRNA,Long ncRNAs,RNA, Long Non-Translated,lncRNA,Long Intergenic Non Protein Coding RNA,Long Non Coding RNA,Long Non Protein Coding RNA,Long Non-Translated RNA,Long Untranslated RNA,Non-Coding RNA, Long,Non-Protein-Coding RNA, Long,Non-Translated RNA, Long,Noncoding RNA, Long,RNA, Long Non Translated,RNA, Long Non-Coding,RNA, Long Non-Protein-Coding,Untranslated RNA, Long,ncRNA, Long,ncRNAs, Long
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
December 2020, Cancer medicine,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
January 2020, OncoTargets and therapy,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
January 2022, Journal of immunology research,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
June 2021, Human & experimental toxicology,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
January 2021, Molecular and cellular biochemistry,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
September 2018, Journal of cellular physiology,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
November 2020, Pathology, research and practice,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
January 2019, OncoTargets and therapy,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
December 2020, Regenerative therapy,
Juanjuan Dai, and Ning Zhou, and Rui Wu, and Jing Du, and Shuang Miao, and Kaikai Gong, and Lijuan Yang, and Weiwei Chen, and Xuelin Li, and Chen Li, and Yan Wu
May 2021, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!